Tradestie Institutional Equity Comparison Engine
STTK vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
STTK Overall Edge
STTK Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Shattuck Labs, Inc. Common Stock (STTK) driven by superior Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, STTK trades at N/M Forward P/E with 0.0% operating margin (-66.6% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, STTK sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
STTK N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -66.6% vs -62.7%
Momentum & Technical Winner
STTK
1Y +147.8% vs -77.5% ยท 52W Pos 43% vs 10%
Options & Structure Winner
STTK
BREAKDOWN (10th %ile IV) vs BREAKDOWN (N/A IV)
STTK
NASDAQ
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.56
-1.94% 1D
Market Cap
$474.6M
1M Return
-15.87%
1Y Return
+147.83%
Forward P/E
N/M
Unified AI Score
51.1 / 100
HOLD
Tech 48.0
Fund 58.0
Flow 63.0
Mom 60.0
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
STTK +147.83%
CVM -77.48%
Spread: +218.53 pp (STTK Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | STTK Revenue | CVM Revenue | STTK Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2014 | N/A | $0M | N/A | -9721.4% | CVM |
| FY2019 | $10M | N/A | -253.5% | N/A | STTK |
| FY2020 | $10M | N/A | -371.8% | N/A | STTK |
| FY2021 | $30M | N/A | -150.8% | N/A | STTK |
| FY2022 | $0M | N/A | -15848.0% | N/A | STTK |
| FY2023 | $0M | N/A | -5549.6% | N/A | STTK |
| FY2024 | $10M | N/A | -1408.3% | N/A | STTK |
| FY2025 | $0M | N/A | -5150.8% | N/A | STTK |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | STTK | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $474.6M | $20.9M | Larger Scale | STTK |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | -66.6% | -62.7% | Higher Growth | CVM |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -47.2% | -252.5% | Higher ROE | STTK |
| 52-Week Range Position Momentum | 43% ($2โ$8) | 10% ($1โ$8) | Stronger Trend | STTK |
| Beta / 30D Volatility Risk Regime | 1.48ฮฒ ยท 78% Vol | 0.65ฮฒ ยท 120% Vol | Lower Realized Risk | STTK |
| Unified Institutional Score Composite Signal | 51.1 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full STTK vs CVM Buy Guide
STTK
BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither STTK nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.